Search Videos by Topic or Participant
Browse by Series:

Sequencing Checkpoint Inhibitors in NSCLC

Panelists: Robert Dreicer, MD, Cleveland Clinic; Omid Hamid, MD, Angeles Clinic;Roy S. Herbst, MD, PhD, Yale; Mark A. Socinski, MD, UPMC; Louis
Published: Saturday, Jan 24, 2015
For High-Definition, Click
With PD-1 inhibitors rapidly becoming available for patients with non-small cell lung cancer, the next questions facing researchers will be optimal sequences for these agents with targeted therapies. In patients with EGFR mutations, where a response to a TKI is expected, starting with a PD-1 inhibitor could result in better outcomes. However, some might reserve the PD-1 inhibitor until resistance occurs.

As clinical trials begin to show the benefits associated with PD-1 inhibitors in NSCLC, the need for a better biomarker will be enhanced.

View the video, to hear the discussion.


Slider Left
Slider Right
For High-Definition, Click
With PD-1 inhibitors rapidly becoming available for patients with non-small cell lung cancer, the next questions facing researchers will be optimal sequences for these agents with targeted therapies. In patients with EGFR mutations, where a response to a TKI is expected, starting with a PD-1 inhibitor could result in better outcomes. However, some might reserve the PD-1 inhibitor until resistance occurs.

As clinical trials begin to show the benefits associated with PD-1 inhibitors in NSCLC, the need for a better biomarker will be enhanced.

View the video, to hear the discussion.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x